A Phase IV Enhanced Safety Surveillance Study of ACAM2000 in Military Personnel.

Trial Profile

A Phase IV Enhanced Safety Surveillance Study of ACAM2000 in Military Personnel.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs ACAM 2000 (Primary)
  • Indications Smallpox
  • Focus Adverse reactions
  • Sponsors Emergent BioSolutions; Sanofi; sanofi pasteur
  • Most Recent Events

    • 26 Jan 2018 Status changed from active, no longer recruiting to completed.
    • 16 May 2017 Planned End Date changed from 1 Sep 2016 to 1 Dec 2017.
    • 16 May 2017 Planned primary completion date changed from 1 Apr 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top